Bivin & Associates’s AbbVie ABBV Stock Holding History

Bivin & Associates’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-35	Closed	-$6K	–	315
2022 Q1	$6K	Buy	35 +10	+40%	+$1.45K	0.01%	195
2021 Q4	$3K	Buy	+25	New	+$2.95K	﹤0.01%	229

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bivin & Associates's ABBV Position: Q2 2022 in Review

Bivin & Associates sold out of AbbVie (ABBV) in Q2 2022, closing a stake of 35 shares — an estimated $6K sold.

Bivin & Associates first reported a position in ABBV in Q4 2021 and held it in 2 quarters. The position peaked at $6K in Q1 2022. 3,005 funds tracked by Wall St. Rank hold ABBV as of Q2 2022.

Bivin & Associates reported no remaining AbbVie position as of Q2 2022 after selling out during the quarter.
Bivin & Associates sold 35 AbbVie shares in Q2 2022, an estimated $6K.
Bivin & Associates first reported a position in AbbVie in Q4 2021 and held it in 2 quarters.
Bivin & Associates's AbbVie position peaked at $6K in Q1 2022.
3,005 funds tracked by Wall St. Rank held AbbVie as of Q2 2022.

Based on Bivin & Associates's 13F filing for Q2 2022, filed 11 Aug 2022.